SG11201602815YA - Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy - Google Patents
Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapyInfo
- Publication number
- SG11201602815YA SG11201602815YA SG11201602815YA SG11201602815YA SG11201602815YA SG 11201602815Y A SG11201602815Y A SG 11201602815YA SG 11201602815Y A SG11201602815Y A SG 11201602815YA SG 11201602815Y A SG11201602815Y A SG 11201602815YA SG 11201602815Y A SG11201602815Y A SG 11201602815YA
- Authority
- SG
- Singapore
- Prior art keywords
- cbp
- cancer immunotherapy
- bromodomain inhibitors
- bromodomain
- inhibitors
- Prior art date
Links
- 102000001805 Bromodomains Human genes 0.000 title 1
- 108050009021 Bromodomains Proteins 0.000 title 1
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890041P | 2013-10-11 | 2013-10-11 | |
| PCT/US2014/060147 WO2015054642A2 (en) | 2013-10-11 | 2014-10-10 | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201602815YA true SG11201602815YA (en) | 2016-05-30 |
Family
ID=52813753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201602815YA SG11201602815YA (en) | 2013-10-11 | 2014-10-10 | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160317632A1 (en) |
| EP (1) | EP3054966A4 (en) |
| JP (1) | JP2016534044A (en) |
| KR (1) | KR20160060765A (en) |
| CN (1) | CN105979958A (en) |
| AU (1) | AU2014331697A1 (en) |
| BR (1) | BR112016007891A2 (en) |
| CA (1) | CA2926946A1 (en) |
| IL (1) | IL245016A0 (en) |
| MX (1) | MX2016004570A (en) |
| RU (1) | RU2016118008A (en) |
| SG (1) | SG11201602815YA (en) |
| WO (1) | WO2015054642A2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5935030B2 (en) | 2010-05-14 | 2016-06-15 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Compositions and methods for treating leukemia |
| EP2571503B1 (en) | 2010-05-14 | 2015-01-07 | Dana-Farber Cancer Institute, Inc. | Compositions and their use in treating neoplasia, inflammatory disease and other disorders |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| SG11201607108XA (en) | 2014-02-28 | 2016-09-29 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia |
| JP6715243B2 (en) | 2014-10-27 | 2020-07-01 | テンシャ セラピューティクス，インコーポレイテッド | Bromodomain inhibitor |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2016196173A1 (en) * | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
| MA43037A (en) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Inst Inc | BROMODOMAIN INHIBITOR POLYTHERAPY AND CHECKPOINT BLOCKING |
| WO2017078049A1 (en) * | 2015-11-04 | 2017-05-11 | アステラス製薬株式会社 | Pharmaceutical composition for cancer immunotherapy purposes and/or immunostimulation purposes which contains diamino heterocyclic carboxamide compound as active ingredient |
| SG11201900446QA (en) * | 2016-07-25 | 2019-02-27 | Epizyme Inc | Crebbp related cancer therapy |
| US11414384B2 (en) | 2018-02-16 | 2022-08-16 | Constellation Pharmaceuticals, Inc. | P300/CBP hat inhibitors |
| CN112218857B (en) * | 2018-02-16 | 2023-11-21 | 星座制药公司 | P300/CBP HAT inhibitors and methods of use thereof |
| TW202028222A (en) * | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Modulators of foxp3 expression |
| AU2020295399A1 (en) * | 2019-06-18 | 2021-12-02 | Dana-Farber Cancer Institute, Inc. | Small molecule target bromo/acetyl proteins and uses thereof |
| CN110170052B (en) * | 2019-06-21 | 2020-07-10 | 复旦大学 | Application of CBP-P300 inhibitor in intestinal injury diseases |
| CN110938630B (en) * | 2019-12-20 | 2023-07-28 | 中国人民解放军第四军医大学 | Application of human B3GNT5 gene and related products |
| CN115701996A (en) * | 2020-06-25 | 2023-02-14 | 托雷莫治疗股份公司 | Combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for the treatment of EGFR mutant NSCLC |
| WO2022184664A1 (en) | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120028912A1 (en) * | 2000-02-22 | 2012-02-02 | J.David Gladstone Institute | Methods of modulating bromodomains |
| IN2014MN02330A (en) * | 2007-06-21 | 2015-08-14 | Wistar Inst | |
| EP2239264A4 (en) * | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | Antitumor agent |
| GB201020015D0 (en) * | 2010-11-25 | 2011-01-12 | Glaxo Group Ltd | Method of treatment |
| EP2677865A4 (en) * | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
| US10071129B2 (en) * | 2011-08-30 | 2018-09-11 | Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. | Method for identifying bromodomain inhibitors |
| WO2013192274A2 (en) * | 2012-06-19 | 2013-12-27 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| CN107073125A (en) * | 2014-09-19 | 2017-08-18 | 基因泰克公司 | CBP/EP300 and BET inhibitor is used for the purposes for the treatment of cancer |
-
2014
- 2014-10-10 AU AU2014331697A patent/AU2014331697A1/en not_active Abandoned
- 2014-10-10 CA CA2926946A patent/CA2926946A1/en not_active Abandoned
- 2014-10-10 WO PCT/US2014/060147 patent/WO2015054642A2/en active Application Filing
- 2014-10-10 SG SG11201602815YA patent/SG11201602815YA/en unknown
- 2014-10-10 RU RU2016118008A patent/RU2016118008A/en not_active Application Discontinuation
- 2014-10-10 BR BR112016007891A patent/BR112016007891A2/en not_active IP Right Cessation
- 2014-10-10 CN CN201480067309.0A patent/CN105979958A/en active Pending
- 2014-10-10 JP JP2016521742A patent/JP2016534044A/en not_active Withdrawn
- 2014-10-10 KR KR1020167011914A patent/KR20160060765A/en not_active Application Discontinuation
- 2014-10-10 EP EP14853063.7A patent/EP3054966A4/en not_active Withdrawn
- 2014-10-10 MX MX2016004570A patent/MX2016004570A/en unknown
-
2016
- 2016-04-10 IL IL245016A patent/IL245016A0/en unknown
- 2016-04-11 US US15/095,985 patent/US20160317632A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3054966A2 (en) | 2016-08-17 |
| RU2016118008A (en) | 2017-11-16 |
| WO2015054642A2 (en) | 2015-04-16 |
| US20160317632A1 (en) | 2016-11-03 |
| AU2014331697A9 (en) | 2016-05-26 |
| RU2016118008A3 (en) | 2018-07-25 |
| IL245016A0 (en) | 2016-05-31 |
| KR20160060765A (en) | 2016-05-30 |
| WO2015054642A9 (en) | 2016-04-28 |
| EP3054966A4 (en) | 2017-04-19 |
| CN105979958A (en) | 2016-09-28 |
| WO2015054642A3 (en) | 2015-06-04 |
| CA2926946A1 (en) | 2015-04-16 |
| MX2016004570A (en) | 2016-09-08 |
| AU2014331697A1 (en) | 2016-05-05 |
| JP2016534044A (en) | 2016-11-04 |
| BR112016007891A2 (en) | 2017-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245016A0 (en) | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy | |
| IL289821A (en) | Compositions and methods for immunotherapy | |
| ZA201800854B (en) | Novel bicyclic bromodomain inhibitors | |
| EP3079707A4 (en) | Immunotherapy of cancer | |
| ZA201703585B (en) | Combination immunotherapy approach for treatment of cancer | |
| HK1220387A1 (en) | Compositions and methods for immunotherapy | |
| IL285527A (en) | Compositions and methods for immunotherapy | |
| PL3089749T3 (en) | Combined preparations for the treatment of cancer | |
| EP2956170A4 (en) | Composition and method for diagnosis and immunotherapy of lung cancer |